LDN, Cortisol, Adaptogens, Titration Strategies, Ketosis, and Methylene Blue: An Integrative Clinical Perspective

Yoon Hang Kim, MD, MPH

Board-Certified in Preventive Medicine 

Osher Fellow, University of Arizona Integrative Medicine Fellowship  | www.directintegrativecare.com

MEDICAL DISCLAIMER: This article is intended for educational and informational purposes only and does not constitute medical advice, diagnosis, or treatment. The information presented here reflects clinical observations and a review of the published literature. It should not be used as a substitute for professional medical consultation. Always consult a qualified healthcare provider before starting, changing, or discontinuing any medication, supplement, or dietary intervention. Individual responses to treatments vary, and what works for one person may not be appropriate for another.

Introduction

In clinical integrative medicine, managing anxiety, cortisol dysregulation, and immune dysfunction often requires a layered, individualized approach. Rather than relying on a single intervention, thoughtful clinicians combine low-dose naltrexone (LDN), adaptogenic herbs, dietary strategies such as nutritional ketosis, and emerging compounds like methylene blue into coordinated therapeutic regimens. The challenge lies not in identifying which tools are available, but in understanding how they interact, when to combine them, and how to titrate them safely for each patient.

This article explores the clinical reasoning behind combining these modalities, drawing on published evidence and practical experience in integrative practice. The emphasis throughout is on individualization, gradual dose adjustment, and keeping the therapeutic goal clearly in view.

Cortisol, Anxiety, and the Role of Adaptogens

Anxiety in the integrative medicine setting often has a neuroendocrine component. Elevated cortisol, whether from chronic psychosocial stress, HPA axis dysregulation, or inflammatory conditions, can both drive and perpetuate anxiety symptoms. Identifying cortisol excess as a contributing factor opens the door to adaptogenic interventions that work upstream of the symptom.

A helpful way to think about supplements and medications is to treat them like relationships between people. Even things that work well together can occasionally conflict. The key question is always: what outcome are we trying to achieve? When both anxiety and cortisol dysregulation are present, the clinician must decide which target takes priority and select accordingly.

Rhodiola rosea has emerged as one of the best-studied adaptogens for stress-related conditions. The European Medicines Agency has approved its traditional use for the temporary relief of stress symptoms, and clinical trials have demonstrated its capacity to reduce cortisol response to awakening stress in patients with burnout and fatigue syndrome (1,2). In animal models, Rhodiola rosea root powder significantly reduced both anxiety-like behavior and serum corticosterone levels under chronic stress conditions, supporting both anxiolytic and adaptogenic properties (3). Its mechanism appears to involve modulation of the hypothalamic-pituitary-adrenal axis, including downregulation of hypothalamic corticotropin-releasing hormone expression and suppression of stress-activated protein kinase phosphorylation (4,5).

A small open-label pilot study in patients with generalized anxiety disorder found that 340 mg of Rhodiola rosea extract for 10 weeks produced significant reductions in Hamilton Anxiety Rating Scale scores, with 50 percent of participants meeting responder criteria and 40 percent achieving remission (6). While larger trials are needed, these early results are encouraging.

Ashwagandha (Withania somnifera) is the other major adaptogen commonly discussed alongside rhodiola. Meta-analyses of randomized controlled trials have confirmed that ashwagandha significantly reduces perceived stress, anxiety scores, and serum cortisol levels compared with placebo (7,8). A 60-day trial using a standardized extract demonstrated improvements on the GAD-7 and Perceived Stress Scale alongside reductions in morning cortisol and increases in serotonin (9).

In traditional medicine systems, rhodiola and ashwagandha are often viewed as complementary, much like balancing principles. However, in clinical practice, sequencing matters. If anxiety is the dominant symptom, it may be preferable to begin with rhodiola alone, as ashwagandha can occasionally produce paradoxical worsening of anxiety or restlessness in some individuals early in treatment. This appears related to its effects on thyroid function and cortisol rhythm modulation (10). Once the patient is stable on rhodiola, ashwagandha can be introduced as a second agent. Some clinicians combine them in roughly a two-to-one ratio favoring rhodiola when both are used simultaneously.

Layering Adaptogens with LDN

Low-dose naltrexone occupies a unique space in integrative medicine as an immune-modulating agent with effects on endorphin signaling, glial cell activity, and inflammatory cytokine balance. When patients are taking LDN for autoimmune or inflammatory conditions and also present with anxiety and cortisol dysregulation, the question arises whether adaptogenic herbs can be safely combined.

In clinical practice, these approaches are often layered together. LDN can be combined with adaptogenic supplements when appropriate, provided the clinician maintains awareness of the therapeutic goals and monitors for unexpected interactions. Rhodiola, with its dual action on stress regulation and mood balance, can be particularly helpful for patients dealing with both anxiety and cortisol dysregulation while taking LDN. The adaptogenic herbs do not appear to interfere with the opioid receptor dynamics that underlie LDN’s mechanism of action, though formal interaction studies are lacking.

The relational metaphor remains useful here: even agents that work well together can occasionally conflict, and the clinician’s role is to remain attentive to the patient’s response rather than assuming that more interventions always yield better results.

The Principle of Gradual Titration

One of the most important and often underappreciated principles in integrative medicine is individualized titration. Dose adjustments should reflect the patient’s unique physiology, sensitivity, and symptom trajectory. Some patients tolerate increases of 10 percent or more without difficulty, while others require extremely small increments—even in the microgram or nanogram range.

This is especially true with LDN, where the therapeutic window is narrow and individual variation is substantial. In rare cases, patients must dilute their medication to extremely small doses and increase only in tiny steps. If symptoms worsen significantly during an uptitration, the best approach is often to pause, allow the body to stabilize, and then retry at a lower level. Forcing progress through worsening symptoms rarely serves the patient well.

This approach reflects the principle of Occam’s razor, which suggests that simpler explanations and solutions are often preferable to complex ones. When a patient with autoimmune symptoms has failed steroid therapy, for example, a simpler metabolic intervention—such as dietary ketosis—may produce meaningful improvements where pharmacological complexity did not. The same principle applies to dosing: the simplest effective dose, reached gradually, is usually the right one.

Ketosis and Anxiety: A Metabolic Approach

Nutritional ketosis has gained increasing attention as a metabolic intervention for neuropsychiatric conditions. The emerging field of metabolic psychiatry, pioneered at Stanford Medicine, posits that many psychiatric disorders involve fundamental metabolic disturbances within neurons—including insulin resistance, neuroinflammation, oxidative stress, and neurotransmitter imbalances—that can be modulated through ketogenic dietary therapy (11).

A 2025 systematic review and meta-analysis including 50 studies and over 41,000 participants found that ketogenic diets were associated with modest improvements in depressive symptoms in randomized controlled trials, particularly when biochemical ketosis was verified. However, evidence for anxiety reduction in RCTs was inconclusive, though quasi-experimental studies showed more promising results (12). A case series from a specialized metabolic psychiatry practice reported complete remission of both major depression and generalized anxiety disorder within 7 to 12 weeks of achieving therapeutic nutritional ketosis (13).

In clinical observation, ketosis appears to help control anxiety for some individuals, likely through its effects on GABA-to-glutamate ratios, reduced neuroinflammation, and stabilization of neuronal energy metabolism by providing ketone bodies as an alternative fuel source to glucose (14). However, ketosis may not significantly improve depression in all patients, and in those cases, supporting neurotransmitter systems through other mechanisms—including adaptogenic herbs, targeted amino acid therapy, or compounds like methylene blue—may be necessary.

As with all interventions in this space, individual responses vary considerably, and clinical supervision is essential to manage potential adverse effects and adherence challenges.

Methylene Blue: Intermittent Dosing and Mitochondrial Support

Methylene blue is one of the oldest synthetic compounds in medicine, with a well-established safety profile at therapeutic doses and emerging evidence for neuroprotective and cognitive-enhancing properties. Its primary mechanism of interest in integrative neurology is its ability to serve as an alternative electron carrier in the mitochondrial electron transport chain, rerouting electrons from NADH to cytochrome c and thereby increasing complex IV activity, promoting ATP synthesis, and reducing reactive oxygen species production (15,16).

Low-dose methylene blue exhibits a hormetic dose-response pattern: low doses enhance mitochondrial function and provide neuroprotection, while high doses can become pro-oxidant and counterproductive (17). A randomized, double-blind, placebo-controlled trial in healthy adults demonstrated that a single 280 mg oral dose modulated functional brain connectivity in regions associated with working memory, visual processing, and motor coordination (18). Oral methylene blue also demonstrates high absolute bioavailability when given as an aqueous formulation (19).

One clinical strategy involves intermittent use of methylene blue at low oral doses—roughly 10 to 20 mg several times daily for a few days each week, followed by several days without it to allow the body to reset. When urine is no longer blue, it indicates the compound has been cleared. This cycling approach may help maintain sensitivity to the compound and prevent tolerance development, though formal studies of this specific protocol are lacking.

Overall, methylene blue appears relatively safe at typical low oral doses. Higher-risk complications, including hemolysis in G6PD-deficient individuals and serotonin syndrome when combined with serotonergic medications, tend to occur primarily with intravenous dosing or at higher doses (20). The FDA has issued warnings about combining methylene blue with SSRIs, SNRIs, and MAO inhibitors due to its inherent MAO-A inhibitory activity (21). Oral dosing at low levels may also involve natural absorption limits that attenuate the risk of excessive uptake, though this remains an area requiring further study.

As with all the interventions discussed here, methylene blue should be used under clinical supervision, and patients must disclose all concurrent medications to avoid potentially dangerous interactions.

Synthesis: Individualized, Layered, Goal-Directed Care

The common thread linking LDN, adaptogens, titration strategies, ketosis, and methylene blue is the principle of individualization. No single protocol fits every patient, and the art of integrative medicine lies in matching the intervention to the person rather than the diagnosis. Cortisol dysregulation in one patient may respond beautifully to rhodiola alone; in another, it may require the addition of ashwagandha, dietary changes, and careful LDN titration.

The relational metaphor for supplements and medications—treating them like relationships between people—is worth returning to. Even well-matched agents can conflict in certain contexts, and the clinician must remain nimble, willing to simplify when complexity fails, and always guided by the question: what outcome are we trying to achieve?

In a field that sometimes errs toward therapeutic maximalism, these principles offer a corrective. Start low. Go slow. Keep it simple when you can. And always listen to the patient’s body as closely as you listen to the literature.

References

1. Olsson EM, von Schéele B, Panossian AG. A randomised, double-blind, placebo-controlled, parallel-group study of the standardised extract SHR-5 of the roots of Rhodiola rosea in the treatment of subjects with stress-related fatigue. Planta Med. 2009;75(2):105-112.

2. Anghelescu IG, Edwards D, Seifritz E, Kasper S. Stress management and the role of Rhodiola rosea: a review. Int J Psychiatry Clin Pract. 2018;22(4):242-252.

3. Rhodiola rosea L. roots powder strongly reduces anxiety and corticosterone level induced by chronic stress in a murine model. PMC. 2025.

4. Panossian A, Hambardzumyan M, Hovhanissyan A, Wikman G. The adaptogens rhodiola and schizandra modify the response to immobilization stress in rabbits by suppressing the increase of phosphorylated stress-activated protein kinase, nitric oxide and cortisol. Drug Target Insights. 2007;2:39-54.

5. Panossian A, Wikman G, Sarris J. Rosenroot (Rhodiola rosea): traditional use, chemical composition, pharmacology and clinical efficacy. Phytomedicine. 2010;17(7):481-493.

6. Bystritsky A, Kerwin L, Feusner JD. A pilot study of Rhodiola rosea (Rhodax) for generalized anxiety disorder (GAD). J Altern Complement Med. 2008;14(2):175-180.

7. Akhgarjand C, Asoudeh F, Bagheri A, et al. Does ashwagandha supplementation have a beneficial effect on the management of anxiety and stress? A systematic review and meta-analysis of randomized controlled trials. Phytother Res. 2022;36(11):4115-4124.

8. Dey A, Chatterjee SS, Hegde S, et al. Effects of Ashwagandha (Withania somnifera) on stress and anxiety: a systematic review and meta-analysis. Explore (NY). 2024;S1550-8307(24)00169-1.

9. Majeed M, Nagabhushanam K, Mundkur L. A standardized Ashwagandha root extract alleviates stress, anxiety, and improves quality of life in healthy adults by modulating stress hormones: results from a randomized, double-blind, placebo-controlled study. Medicine (Baltimore). 2023;102(41):e35521.

10. Lopresti AL, Smith SJ, Malvi H, Kodgule R. An investigation into the stress-relieving and pharmacological actions of an ashwagandha (Withania somnifera) extract: a randomized, double-blind, placebo-controlled study. Medicine (Baltimore). 2019;98(37):e17186.

11. Norwitz NG, Sethi S, Palmer CM. Ketogenic diet as a metabolic treatment for mental illness. Curr Opin Endocrinol Diabetes Obes. 2020;27(5):269-274.

12. Diab J, et al. Ketogenic diets and depression and anxiety: a systematic review and meta-analysis. JAMA Netw Open. 2025.

13. Danan A, Westman EC, Saslow LR, Ede G. Complete remission of depression and anxiety using a ketogenic diet: case series. Front Nutr. 2024;11:1396685.

14. Sethi S, et al. Ketogenic diet improves serious mental illness. Psychiatry Res. 2024.

15. Poteet E, Winters A, Yan LJ, et al. Neuroprotective actions of methylene blue and its derivatives. PLoS One. 2012;7(10):e48279.

16. Yang SH, Li W, Sumien N, et al. From mitochondrial function to neuroprotection—an emerging role for methylene blue. Mol Neurobiol. 2017;55(8):6137-6153.

17. Rojas JC, Bruchey AK, Gonzalez-Lima F. Neurometabolic mechanisms for memory enhancement and neuroprotection of methylene blue. Prog Neurobiol. 2012;96(1):32-45.

18. Rodriguez P, Singh AP, Malloy KE, et al. Methylene blue modulates functional connectivity in the human brain. Brain Imaging Behav. 2017;11(3):640-648.

19. Walter-Sack I, Rengelshausen J, Oberwittler H, et al. High absolute bioavailability of methylene blue given as an aqueous oral formulation. Eur J Clin Pharmacol. 2009;65(2):179-189.

20. Bistas KG, Sanghavi DK. Methylene Blue. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2025.

21. U.S. Food and Drug Administration. FDA Drug Safety Communication: serious CNS reactions possible when methylene blue is given to patients taking certain psychiatric medications. 2019.